Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
7
Expiration
Mar 19, 2027
DTE
150d
Moneyness
OTM
Intrinsic
$0.00
IBRX 7 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.05 | +0.00% | 10 | 1,102 |
| Oct 30, 2026 | 10d | $0.05 | -50.00% | 1 | 78 |
| Nov 6, 2026 | 17d | $0.11 | +0.00% | 11 | 11 |
| Nov 13, 2026 | 24d | $0.20 | -60.00% | 800 | 1,099 |
| Nov 20, 2026 | 31d | $0.25 | +66.67% | 1,067 | 3,286 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $0.95 | -9.52% | 5 | 420 |
| Apr 16, 2027 | 178d | $1.37 | -9.87% | 1 | 2 |
| May 21, 2027 | 213d | $1.25 | -53.87% | 1 | 11 |
| Aug 20, 2027 | 304d | $2.00 | -28.06% | 3 | 4 |
| Nov 19, 2027 | 395d | $2.25 | +28.57% | 52 | 1,751 |
| Mar 17, 2028 | 514d | $2.30 | +12.20% | 2 | 91 |
| Jan 19, 2029 | 822d | $2.50 | -3.85% | 5 | 27 |
IBRX Nearby Strikes · Mar 19, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 1 P | — | — | 0 | 0 | OTM |
| 2 P | $0.05 | +0.00% | 1 | 1 | OTM |
| 3 P | $0.45 | +200.00% | 1 | 1 | OTM |
| 4 P | $0.33 | -48.44% | 1 | 14 | OTM |
| 5 P | $0.35 | +0.00% | 8 | 130 | OTM |
| 6 P | $0.59 | -34.44% | 5 | 354 | OTM |
| 7 P | $0.95 | -9.52% | 5 | 420 | OTM |
| 8 P | $1.36 | -15.00% | 292 | 733 | OTM |
| 9 P | $1.84 | -10.68% | 20 | 137 | ITM |
| 10 P | $2.40 | -4.00% | 10 | 68 | ITM |
| 11 P | $3.40 | -32.00% | 4 | 5 | ITM |
| 12 P | $4.10 | +2.24% | 3 | 43 | ITM |
| 13 P | $4.80 | +0.00% | 3 | 3 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.